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Abstract
The primate-exclusive MRGPRX2 G protein-coupled receptor (GPCR) has been suggested to 
modulate pain and itch. Despite putative peptide and small molecule MRGPRX2 agonists, 
selective nanomolar potency probes have not yet been reported. To identify a MRGPRX2 probe, 
we first screened 5,695 small molecules and found many opioid compounds activated MRGPRX2, 
including (−)- and (+)-morphine, hydrocodone, sinomenine, dextromethorphan and the 
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prodynorphin-derived peptides, dynorphin A, dynorphin B, and α- and β-neoendorphin. We used 
these to select for mutagenesis-validated homology models and docked almost 4 million small 
molecules. From this docking, we predicted ZINC-3573, which represents a potent MRGPRX2-
selective agonist, showing little activity against 315 other GPCRs and 97 representative kinases, 
and an essentially inactive enantiomer. ZINC-3573 activates endogenous MRGPRX2 in a human 
mast cell line inducing degranulation and calcium release. MRGPRX2 is a unique atypical opioid-
like receptor important for modulating mast cell degranulation, which can now be specifically 
modulated with ZINC-3573.
G protein-coupled receptors (GPCRs) are seven transmembrane receptors that transduce 
extracellular signals into biological responses via heterotrimeric G-proteins and β-arrestins1. 
GPCRs are involved in nearly every known biological system and, unsurprisingly, GPCR-
targeting small molecules represent the largest target class for FDA-approved drugs2. 
Despite their therapeutic utility, only 10% of GPCRs function as therapeutic targets for FDA 
approved drugs2, while ~120 of 394 non-olfactory GPCRs represent “orphan receptors” or 
understudied GPCRs (“oGPCRs”3) without useful probes and, frequently, without validated 
endogenous ligands4,5. The process of discovering specific and potent probes for oGPCRs 
yields useful research tools and can also illuminate previously unrealized drug interactions, 
potentially establishing new drug targets.
To identify oGPCR ligands, we have developed and tested new physical and computational 
approaches for screening these receptors. The first physical method, dubbed “PRESTO-
Tango,” involves high-throughput, massively parallel screening of potential modulators 
(including small molecules, bioactive peptides, and other reagents) for their ability to 
stimulate β-arrestin recruitment at most non-olfactory receptors in the GPCRome6. The 
second orthogonal and complementary approach relies on the principle that over-expressed 
G proteins facilitate a partially active state for most GPCRs enabling the discovery of both 
allosteric and orthosteric modulators for oGPCRs using engineered yeast3. Encouraged by 
the success of other structure-based drug design methods in GPCRs7–9, our in silico 
approach leverages the physical screens to develop comparative structural models of the 
receptors, and then computationally screens a much wider chemical space—typically several 
million commercially available molecules—to find specific ligands for the oGPCRs.
We apply this strategy to the Mas-related G protein-coupled receptor X2 (MRGPRX2) -- a 
primate-exclusive10,11 class A orphan GPCR expressed in mast cells and small diameter 
neurons in the dorsal root and trigeminal ganglia12–16. Several unrelated peptides are 
reported to activate MRGPRX2 including Cortistatin-1416, Substance P13, and PAMP(9–
20)14, whether any proposed peptides are endogenous MRGPRX2 agonists is unknown. 
MRGPRX2 remains an oGPCR in part because no convincing rodent ortholog has been 
validated (see Discussion) and because MRGPRX2-selective nanomolar potency probes are 
unavailable. Although several selective agonists are reported for MRGPRX217,18, the 
compounds are not easily obtained and have not been validated for specificity or potency. 
The identification of demonstrably selective, potent MRGPRX2 agonist probes represents an 
essential step toward illumination of its function in vitro and in vivo.
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Here, we describe how an integrated approach combining our PRESTO –Tango method and 
our modeling and docking platforms led to the identification of MRGPRX2 agonists, 
including exogenous and endogenous opioids and a selective MRGPRX2 probe ZINC-3573. 
We confirmed ZINC-3573’s selectivity for MRGPRX2 via testing at 315 class A GPCRs 
using PRESTO-Tango, binding assays performed by the National Institute of Mental Health 
Psychoactive Drug Screening Program (NIMH-PDSP), and by testing the parent scaffold 
using a commercial (DiscoverX) kinome screen. Using ZINC-3573, we show MRGPRX2 
activation induces intracellular calcium release and degranulation in a human mast cell line. 
We also demonstrate that MRGPRX2 represents a novel Gαq-coupled opioid-like receptor 
that could mediate some peripheral side effects of commonly prescribed opiate medications. 
This discovery of the specific MRGPRX2 agonist ZINC-3573, matched with an inactive 
enantiomer, provides the community with a pair of chemical probes by which the in vivo 
function of this fascinating target may be investigated with exquisite specificity and control.
RESULTS
Identification of MRGPRX2 agonists
We initially attempted to replicate prior reports of potential MRGPRX2 agonists to 
determine if any might prove suitable as leads for probe development. Unfortunately, we 
could not replicate the activities of most reported MRGPRX2 agonists when tested at the 
highest concentrations possible for our assays (Fig 1, Supplementary Results, 
Supplementary Table 1). Thus, of the many putative MRGPRX2-activating peptides and 
peptide-like compounds, we could replicate activities only for substance P, cortistatin-14 and 
PAMP (9–20) (Fig 1a,b). Mastoparan, octreotide, leuprolide, and kallidin were inactive or 
only marginally so (e.g. Gαq EC50 = 11.5 μM for kallidin) at human MRGPRX2 (Fig 1c, 
Supplementary Table 1).The putative MRGPRX2 agonist mastoparan19 was active in cells 
with and without MRGPRX2 expression suggesting non-specific activity (Fig 1d., 
Supplementary Table 1).
Of the more than one dozen non-peptide compounds reported to activate MRGPRX2, we 
could only replicate four (TAN-6720, compound 48/8019, cetrorelix19 and the proposed 
selective agonist complanadine A18) and even these had low potencies or have other known 
receptor targets (Fig 1c,d, Supplementary Table 1). Notably, we could not validate several 
recently reported secretagogue agonists for MRGPRX2 including the THIQ motif-
containing octreotide, rocuronium, ciprofloxacin, atracurium, moxifloxacin, and 
levofloxacin19 even when tested up to 100 μM (Fig 1c,d, Supplementary Table 1). Likewise, 
although the proposed nanomolar MRGPRX2-selective agonist complanadine A18 was 
active in our assays, we measured a Gαq EC50 of 18 μM and could not obtain a β-arrestin 
EC50 due to apparent cytotoxicity above 1 μM using PRESTO-Tango, a luciferase reporter-
based β-arrestin screening platform6 (Fig 1c,d, see Supplementary Table 1 for a full list of 
validated compounds).
As MRGPRX2 is expressed only in primates, finding a rodent analog would enable the use 
of genetic techniques to probe for the receptor’s functional roles, with the caveat that 
GPCRs may often be knocked down without incurring phenotypes that recapitulate their 
roles in pharmacology. The suggested MRGPRX2 rodent ortholog MRGPRB219 only shares 
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52% sequence identity with MRGPRX2 (Supplementary Fig 1a) and we could not 
substantiate any proposed shared ligands except for Cortistatin-14, which had high 
micromolar activity at MRGPRB2 (Fig 1e, f, Supplementary Fig 1b). Thus, although there 
have been prior studies of MRGPRX2 and/or MRGPRB2’s pharmacology, many remain 
insufficiently robust for facile replication; and no independent studies have emerged that 
replicate these prior findings.
Accordingly, we chose an unbiased approach to identify reliable MRGPRX2 probes. We 
recently proposed parallel screening strategies3,6 using small libraries of drugs and drug-like 
compounds as fruitful initial approaches to discover active compounds at oGPCRs6. Here we 
screened 5,695 unique compounds for agonist activity at three members of the MRGPRX 
family (MRGPRX1, MRGPRX2, and MRGPRX4) using the PRESTO-Tango platform (see 
Online Methods). Our strategy was to screen against three MRGPRX family receptors in 
parallel to find active compounds with selectivity within the family.
The screening revealed MRGPRX1 had the fewest number of actives (39), followed by 
MRGPRX4 (54), and MRGPRX2 (81) (Fig 2a). We were most interested in compounds 
showing selective MRGPRX2 agonism without apparent activity at other MRGPRX 
receptors. Among the 67 compounds that activated MRGPRX2, and neither MRGPRX1 nor 
MRGPRX4, were five opioid-related ligands ADL-5859, sinomenine, dextromethorphan, 
dextromethorphan’s metabolite dextrorphan, and the previously reported MRGPRX2 ligand 
TAN-6720, a delta opioid receptor agonist.
Confirmatory concentration response curves using the PRESTO-Tango platform indicated 
the five opioid-like compounds had low micromolar potency (Fig 2b, c). To confirm the 
MRGPRX2-Tango construct performed similarly to the unmodified wild-type (WT) 
receptor, we tested previously reported MRGPRX2 agonists TAN-67 20, cortistatin-14 16, 
substance P 13, and compound 48/80 19 and found all activated the MRGPRX2-Tango 
receptor at similar reported potencies for Gαq assays at the WT receptor (Fig 2d).
To confirm MRGPRX2 Gαq-mediated functional activity of agonists, we used a tetracycline-
inducible WT MRGPRX2 stable HEK-T cell line to test for intracellular calcium release. 
Dextromethorphan, dextrorphan, sinomenine, and TAN-67 promoted intracellular calcium 
release when MRGPRX2 expression was induced by tetracycline (1 μg/ml; Supplementary 
Fig 2a) but not in the absence of tetracycline (e.g, MRGPRX2 is not expressed, 
Supplementary Fig 2b).
Preference for dextro-enantiomers and N-methyl scaffolds
As several dextrorotatory opiate ligands activated MRGPRX2, we initially investigated 
ligand stereochemistry, aware that classical opioid receptors prefer levorotary morphinans 
and benzomorphans21. We assayed levorphanol and levallorphan, enantiomers of the 
screening hits dextrorphan and dextromethorphan, respectively, for activity at MRGPRX2 in 
β-arrestin recruitment and calcium mobilization assays. Levorphanol was approximately ten-
fold less potent at MRGPRX2 than dextrorphan and levallorphan was completely inactive up 
to 100 μM (Fig 3a). Likewise the dextrorotary morphinan sinomenine had comparable 
potency to dextrorphan and dextromethorphan at MRGPRX2 (Supplementary Table 2), more 
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potent than sinomenine’s purported activity at the opioid receptors22 (Supplementary Fig. 3). 
MRGPRX2 also preferred dextrorotary benzomorphan compounds, as (−)-cis-
normetazocine was ten-fold less potent compared to (+)-cis-normetazocine (Fig 3b, 
Supplementary Table 2).
To determine if other opioids activated MRGPRX2 with similar stereochemical preferences, 
we tested a panel of 11 morphine and codeine analogues for activity in PRESTO-Tango and 
calcium mobilization assays, including the most common metabolites of morphine and 
codeine. Both (+)- and (−)-morphine enantiomers activated MRGPRX2 with comparable 
potency in PRESTO-Tango and calcium assays, as did (+)- and (−)codeine and thebaine (Fig 
3c,d, Supplementary Table 2; structures in Fig 3e). For the metabolites, we observed 
differential effects of substitutions on C-3 and C-6 positions in the morphine scaffold, as 
replacement of morphine’s 3-hydroxy with a 3-methoxy (e.g. codeine and thebaine) had 
little effect on affinity or efficacy at MRGPRX2 whereas replacement of the morphine’s 3-
hydroxy with gluconuride to yield morphine-3β-gluconuride eliminated MRGPRX2 agonist 
activity (Fig 3c,d, Supplementary Table 2; structures in Fig 3e). In the C-6 position, 
gluconuride or acetyl modifications to morphine and codeine all retained agonist activity, 
albeit with loss in potency compared to (−)-morphine and (−)-codeine, respectively (Fig 3c,d 
Supplementary Table 2). These preliminary opioid structure-activity relationships (SARs) 
demonstrate that larger modifications on C-6 are more tolerated than on C-3.
We then explored the effect of substituents on the cationic nitrogen in the morphinans on 
MRGPRX2 activation. N-methyl substituted scaffolds, as in codeine, morphine, and 
metazocine, conferred receptor agonism while the N-unsubstituted norcodeine was inactive 
up to 100 μM (Fig 3b–d, Supplementary Table 2). Morphinans and benzomorphans with 
substituents larger than N-methyl, such as the N-allyl of levallorphan and N-allyl-
normetazocine, and the N-cyclopropyl of naltrexone and cyclazocine, were inactive at 
MRGPRX2 (Fig 3a,b, Supplementary Table 2). The inactive morphinans and 
benzomorphans showed no antagonist activity against MRGPRX2, suggesting a tight SAR 
around substitution of this position.
As mentioned, TAN-67 is a δ-opioid receptor agonist known to activate MRGPRX220. The 
active enantiomer at the δ-opioid receptor is (−)-TAN-67 whereas (+)-TAN-67 displays pro-
nociceptive activity in vivo through an unidentified receptor23. We tested (+)-TAN-67 for 
MRGPRX2 activity in PRESTO-Tango and calcium mobilization assays and found (+)-
TAN-67 was more potent than racemic (+/−)-TAN-67 (Gαq EC50 = 290 nM vs 740 nM) 
(Supplementary Fig 4), demonstrating that MRGPRX2 prefers dextro-enantiomers at most 
chemical scaffolds with some exceptions. Neither (−)- nor (+)-naloxone antagonized (+/−)-
TAN-67 agonist activity (Supp Fig 5a, b) and no other canonical opioid antagonists, 
including naltrindole, naltrexone, and β-chlornaltrexamine, inhibited (+/−)-TAN-67 activity. 
(Supp Fig 5 c–e). These SARs suggests that MRGPRX2, despite its distant sequence 
relationship to the four classic opioid receptors (transmembrane region sequence identity no 
greater than 26%), is an opioid-responding oGPCR with important differences in ligand 
recognition patterns.
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Prodynorphin-derived peptides activate MRGPRX2
A key question is whether MRGPRX2 is also activated by endogenous opioid ligands. 
Accordingly, we tested a panel of 20 endogenous opioid peptides for activity in PRESTO-
Tango and intracellular calcium assays. MRGPRX2 was preferentially activated by 
prodynorphin-derived peptides (Fig 4a, b) and only minimally activated, if at all, by other 
opioid peptides (Fig 4c, d). The full length dynorphin A (1–17) and several truncated 
prodynorphin peptides activated MRGPRX2 (Fig 4a). C terminal amino acid truncation of 
dynorphin peptides reduced agonist potency until dynorphin A (1–7) and dynorphin A (1–6) 
fragments, which were completely inactive (Fig 4a, Supplementary Fig 6a).
To determine if the C terminal portion of dynorphin A was sufficient for MRGPRX2 
activation, we assayed dynorphin A (13–17) and dynorphin A (6–17) and found that 
dynorphin A (6–17) retained minimal activity (EC50 = 39.6 μM) and dynorphin A (13–17) 
was inactive (Fig 4b), suggesting both the N terminal YGGF motif and C terminal cationic 
tail are important for MRGPRX2 activation (Supplementary Fig 6a). Dynorphin B (1–13) 
and α- and β-neoendorphin also activated MRGPRX2, with dynorphin B and α-
neoendorphin having almost identical μM potency (Fig 4b). Intriguingly, EC50 values for the 
dynorphin peptides were right-shifted in the PRESTO-Tango assay, indicating perhaps 
modest G protein bias, similar to observations made for dynorphin peptides at the κ-opioid 
receptor24.
To determine whether more closely-related receptors might share peptide ligands with 
MRGPRX2, we used the GPCRdb to identify class A receptors with greater than or equal to 
30% sequence similarity to MRGPRX2 in the class A binding pocket (Supplementary Fig 
6b). We identified 14 receptors, 11 of which had established probes (10 ligands total). 3 
receptors were oGPCRs with no known ligands. We tested the 10 established ligands for 
activity and found only one ligand, somatostatin-14, activated MRGPRX2 (Supplementary 
Fig 5b,d; EC50 = 380 nM). This is consistent with previous reports that somatostatin-14, 
somatostatin-28, and Cortistatin-14 are MRGPRX2 agonists16,20. Interestingly, the 
canonical opioid receptors and somatostatin receptors are closely related in binding site-
sequence space, but not in small molecule-chemical space25. Our data, along with previously 
proposed peptide ligands, suggest that although MRGPRX2 can be activated by many 
peptide ligands, this cannot be predicted from sequence similarity alone.
MRGPRX2 is an opioid-like oGPCR that responds to endogenous pro-dynorphin-derived 
opioid peptides, binds to many well-known synthetic opioid agonists, but which differs from 
classic opioid receptors in its unique preference for dextro-morphinans, dextro-
benzomorphans and its inability to be antagonized by potent and classic opioid receptor 
antagonists. Although none of these compounds are suitable as a selective probe or tool, the 
chemical matter identified was useful to launch an in silico campaign to identify novel 
chemotypes active at MRPGRX2.
Structure-based docking predicts MRGPRX2-selective ligands
We next turned to our computational approach using a 1000-fold larger compound library 
than that used in the physical screen—the over 3.7 million commercially available “lead-
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like” molecules then in the ZINC database26. Our strategy was to calculate many 3D 
MRGPRX2 models, select those few that recapitulated the ligand recognition patterns we 
observed experimentally, and use these to template a final model to screen the full, larger 
compound library for novel molecules unrelated to opioid ligands but selective for 
MRGPRX2.
The general approach for modeling and docking has been recently described3, and we 
summarize it here (see Methods for more details). We first sought GPCRs of known 
structure with MRGPRX2 sequence similarity; intriguingly, this led to the κ-opioid receptor, 
which only shares 23.3% sequence identity in the transmembrane regions with MRGPRX2. 
We calculated an initial MRGPRX2 structure using Modeller27 and expanded on this using 
elastic network modeling to increase the amount of sampled backbone conformations28. 
From the initial model, we calculated 360 further structures using the Elastic Network 
Modeling program ENM; half of these had an extracellular disulfide bond imposed and half 
did not. Each of these was expanded three-fold with Modeller (i.e., using the ENM models 
as templates for Modeller). Overall, 1,080 models were calculated.
We docked the 5,695 unique compounds from physical screening against all 1080 models 
(i.e., over 6 million compound-receptor docking calculations, and over 1012 individual 
configurations of the library molecules in the receptor). We looked for models that best 
enriched the discovered opioid agonists over the vast number of inactive decoy molecules. 
The top-enriching models were inspected visually for binding poses that captured sensible 
ion-pairing interactions with the conserved aminergic group of the opioid agonists. This 
prioritized a model that had a background-corrected logAUC for enrichment 29,30 of 8.42—
which happened to be the top-enriching model (this is not always the case, as sometimes the 
top-enriching model does not have sensible geometries31, though usually the model chosen 
is among the best enriching models). Residues within 6 Å of the dextromethorphan pose 
were minimized around the docked ligand with PLOP32, and the 5,695 molecules re-docked. 
Two rounds of docking and PLOP-based refinement led to the final modeled receptor 
conformation, which predicts the opioid agonists making ionic interactions with Glu1644.60 
and Asp1845.36 (Fig 5, showing dextromethorphan). The exact rotamer state of these 
residues allowed some flexibility; i.e., several different rotamers of the Asp/Glu led to 
productive placement of the known agonists (Supplementary Fig 7e).
To test the predicted ion pair between the receptor and the ligands, we made a series of 
mutations at Glu1644.60 and Asp1845.36. E164Q and D184N substitutions retained steric 
properties of the WT residues but removed their negative charges and both resulted in a loss 
of activity for dextromethorphan, (−)-morphine, and related opioids in the PRESTO-Tango 
assay (Fig 5, Supplementary Fig 7a). We then tested the importance of the length of the 
acidic residue via E164D and D184E mutations and observed that E164D increased the Emax 
and reduced the potency of both dextrorphan and morphine (Supplementary Fig 7 a,c) while 
D184E ablated activity of all opioids tested (Fig 5, Supplementary Fig 7a–d). The 
substitutions support the importance of the proposed ionic interaction and the putative 
binding site predicted by the in silico model, suggesting both Glu1644.60 and Asp1845.36 are 
necessary for MRGPRX2 opioid activation.
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As an aside, dynorphin A (1–13) activity was lost with the D184N but not the E164Q 
mutation, suggesting only one of these residues is required for the opioid peptide interaction 
(Supplementary Fig 7d). We modeled the putative MRGPRX2-dynorphin binding site by 
overlaying the MRGPRX2 homology model with the previously published κ-opioid receptor 
docked with dynorphin A (1–13) 33. The N-terminal Tyr1 of dynorphin A (1–13) is 
accommodated within a negatively charged aromatic pocket, whereas Arg7 and Phe4 appear 
to interact with Asp1845.36 (Supplementary Fig 8 a,b,c). The predicted orientation of 
dynorphin A (1–13) at Asp1845.36 and Glu1644.60 shows a clear preference for charged 
interactions between dynorphin A and Asp1845.36, a result supported by the mutagenesis 
results (Supplementary Fig 8d).
With experimental support for the MRGPRX2 comparative model, we proceeded to virtually 
screen the ZINC library for new ligands. Over 3.7 million commercially available molecules 
were docked, each in an average of 926 orientations and 558 conformations; overall 1.9 
trillion docked complexes were sampled and scored (for details, see Methods). We selected, 
purchased, and assayed 20 compounds from the 0.13% of top-ranked compounds for activity 
at MRGPRX2. As there is little scoring difference among the top-ranked molecules, we 
chose molecules following our usual strategy34 and prioritized those with diverse, non-
opioid chemotypes. We deprioritized molecules with apparently high internal energies, 
which the docking scoring function does not well account for34, and prioritized those that 
made ionic interactions with the Asp1845.36/Glu1644.60 pair, similar to the modeled opioids. 
Of the 20 ZINC compounds tested, one, ZINC-72469232 (1, here on referred to as 
ZINC-9232), had substantial activity below 10 μM in PRESTO-Tango and calcium release 
assays (Fig 5). To improve potency, 22 analogs of ZINC-9232 topologically similar to the 
lead were obtained and tested. Of these 22, 7 were active, with the most potent 
ZINC-72453573 (2, from here on referred to as ZINC-3573) having sub micromolar potency 
(EC50 = 760 nM, Fig 5, Supplementary Fig 9). We then assessed whether ZINC-3573 
interacts with the predicted residues Asp1845.36 and Glu1644.60 using the E164Q and 
D184N mutations and found that both eliminated ZINC-3573 agonism at MRGPRX2 (Fig 
5), consistent with the modeling.
ZINC-3573 as a chemical probe for MRGPRX2
To confirm MRGPRX2 selectivity, we tested ZINC-9232 and ZINC-3573 activity at 315 
other human GPCRs using our PRESTO-Tango GPCRome assay. ZINC-9232 and 
ZINC-3573 showed minimal agonist efficacy at receptors other than MRGPRX2 at 10 μM 
(Supplementary Fig 10 a,b). ZINC-9232 was also screened against a panel of 97 
representative human kinases using the DiscoverX KINOMEscan diversity panel; only three 
kinases were modestly inhibited, with IC50 values between 20–30 μM (Supplementary Fig 
11).
These results encouraged us to synthesize both enantiomers of the more potent ZINC-3573, 
originally supplied as a racemic mixture, in an effort to create a pair of differentially active 
molecules that could jointly be used as a chemical probe pair (Supplementary Scheme 1, 
Supplementary Info.). The R-isomer (3) retained an EC50 of 740 nM in PRESTO-Tango and 
a similar EC50 value of 1 μM in the calcium mobilization assay (Supplementary Fig 9). The 
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S-isomer (4) had little activity below concentrations of 100 μM (Supplementary Fig 9). The 
separate activity of the enantiomers makes them highly attractive probes, as one can 
distinguish MRGPRX2 activity (owing to the R-isomer) from general, non-specific activity 
owing to the scaffold and its physical properties (due to either isomer). Each enantiomer was 
further tested using the PRESTO-Tango GPCRome screening platform (Supplementary Fig 
10 c,d), which indicated 21 receptors may be activated at 2-fold or higher by (R)- and (S)-
ZINC-3573; however, subsequent concentration-response studies showed that no other 
receptor was significantly activated by either compound (Supplementary Fig 11).
MRGPRX2 agonists induce degranulation in human mast cells
MRGPRX2 has been implicated in IgE-independent inflammatory responses in mast cells 
using peptide ligands and other non-specific agonists13,15,19, prompting us to investigate 
whether MRGPRX2-selective agonists induce degranulation and mobilize intracellular 
calcium in the LAD2 human mast cell line. ZINC-9232 and ZINC-3573 induced 
intracellular calcium release and degranulation in LAD2 mast cells at comparable potencies 
to assays performed in MRGPRX2-expressing HEK-T cells (Fig 6a,b). For the 
stereochemical pair, only (R)-ZINC-3573 promoted degranulation in LAD2 mast cells (Fig 
6b), consistent with the HEK-T in vitro activity. As expected, MRGPRX2 siRNA 
significantly reduced (R/S)-ZINC-3573-induced degranulation (Fig 6c, p=0.01).
We then considered whether the opioid ligands might activate endogenously expressed 
MRGPRX2 to induce degranulation in mast cells. This is important, in part, because of the 
well-known but enigmatic ‘histamine flush’ associated with many opioids, which is not due 
to engagement of classical opioid receptors. We found (+/−)TAN-67, (+)-morphine, (−)-
morphine and dynorphin A (1–13) produced robust intracellular calcium release in the mast 
cells while the structurally similar κ-opioid receptor agonist (−)-cyclazocine, which does not 
activate MRGPRX2, did not (Fig 6d). Correspondingly, structurally unrelated agonists for 
the κ, δ, and μ opioid receptors (Salvinorin A, BW373U86 and DAMGO, respectively) were 
inactive (Fig 6e). To determine whether MRGPRX2-activating opioids induce degranulation, 
we first tested 10 μM (+/−)-TAN-67 in the presence or absence of biotin-labeled IgE 
antibodies and found that with or without IgE-biotin antibody activation via streptavidin, the 
MRGPRX2-ligand (+/−)-TAN-67 produced 70% degranulation, indicating MRGPRX2-
mediated degranulation is IgE-independent (Fig 6f). MRGPRX2 agonists (+/−)-TAN-67, 
(+)-morphine, (−)-morphine, and dynorphin A (1–13) all promoted degranulation in LAD2 
cells (Fig 6g) while the classical opioid agonists salvinorin A, BW373U86 and DAMGO did 
not (Fig 6h). 10 μM naloxone pretreatment did not influence the EC50 or Emax values of 
MRGPRX2 opioid agonists (Supplementary Fig 12a,b), whereas MRGPRX2 siRNA 
significantly attenuated (+/−)-TAN-67, dynorphin A (1–13), and (−)-morphine-induced 
degranulation (Fig 6c, Supplementary Fig 12c,d). These data suggest MRGPRX2, not the 
canonical opioid receptors, mediates opioid-induced degranulation in human mast cells.
DISCUSSION
Our MRGPRX2 results underscore two major findings. First, the oGPCR MRGPRX2 
responds to opioid drugs and endogenous pro-dynorphin peptides at potentially 
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physiologically relevant concentrations and mediates opioid-induced degranulation in a 
human mast cell line. Although this receptor is not in the opioid receptor family by sequence 
similarity, its agonism by opioid drugs and peptides qualifies it as an atypical opioid receptor 
that responds to morphinan-based opioids and transmitters. A second key result is the 
structure-based discovery of the selective, sub-micromolar MRGPRX2 agonist (R)-
ZINC-3573. This agonist promotes degranulation in mast cells, has no measurable agonism 
at over 315 other GPCRs, and the parent scaffold has little activity against 97 representative 
kinases. The inactive enantiomer (S)-ZINC-3573 and the active (R)-ZINC3573 are an 
effective and internally controlled probe-pair for investigating the biology of this intriguing 
primate-exclusive receptor. The probes will be made available to the community from 
Sigma-Aldrich (#SML1699 and #SML1700).
SAR results show MRGPRX2 is distinct from the canonical opioid receptors. MRGPRX2 
prefers dextro-enantiomers and N-methyl substituted opioid scaffolds whereas opioid 
receptors prefer levo-enantiomer opioids35,21 and tolerate a wider array of N-substituents. In 
further contradistinction to the canonical opioid receptors, MRGPRX2 is Gαq- rather than 
Gαi-coupled. Thus, MRGPRX2 may be classified as an atypical opioid recognizing receptor, 
arguably more an example of convergent evolution within the GPCR family than the 
divergent evolution that relates the four canonical opioid receptors.
MRGPRX2 activation by opiates may be relevant physiologically and therapeutically. We 
found MRGPRX2, not the canonical opioid receptors, mediates morphine and dynorphin A 
(1–13)-induced mast cell degranulation. Morphine and structurally similar analgesics induce 
mast cell histamine release36,37 in humans, resulting in pruritus 38, vasodilation, and 
hypotension that is poorly reversed by naloxone 39,36; these effects are not seen for opioid 
analgesics lacking MRGPRX2 activity, such as fentanyl37. MRGPRX2 may also be involved 
in the efficacy of sinomenine, which is used to treat rheumatoid arthritis due to its histamine-
releasing properties40. Dextromethorphan’s potency at MRGPRX2 is also greater or equal to 
reported Ki values for μ, κ, δ, NMDA, and σ2 receptors21, suggesting MRGPRX2 could 
contribute to dextromethorphan’s side effect profile which includes itch at high doses41. 
Definitive studies in non-human primates are needed to address these hypotheses.
The micromolar potency of pro-dynorphin peptides at MRGPRX2 suggests in vivo receptor 
activation might require close proximity to high local concentrations of dynorphin. Local 
synaptic concentrations of neuropeptides can reach millimolar range42 and dynorphin is 
expressed in MRGPRX2-expressing regions43–45. At such concentrations, dynorphin could 
activate synaptic GPCRs or those expressed in mast cells, which can localize to nerve 
terminals46. Thus, it is conceivable that MRGPRX2 is exposed to activating concentrations 
of dynorphin in vivo.
Structural modeling enabled the discovery of a new scaffold, represented by ZINC-9232 and 
ZINC-3573, unrelated to classical opioids topologically and structurally. The unusual 
specificity of ZINC-3573 against essentially the entire GPCRome and the relevant kinome, 
and the availability of an inactive enantiomer makes this molecule a uniquely useful 
MRGPRX2 probe. Methodologically, we previously used the combination of an initial 
physical compound screen followed by a much larger docking screen to discover probes for 
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oGPCRs3. Identification of ZINC-3573 by a similar approach against a wholly different 
receptor family suggests this approach has broad utility in structure-based drug design.
The modelled MRGPRX2 provided intriguing insights to this receptor’s unique opioid 
pharmacology. MRGPRX2 shares no more than 26% sequence identity with the μ-, κ-, δ- or 
nociceptin-opioid receptors, and its modeled orthosteric binding differs from that of the 
canonical opioid receptors. The cationic nitrogen of the morphinans is recognized by an 
aspartate in the opioid receptors, located in transmembrane (TM) helix 3, position 3.32. The 
residue for cationic nitrogen recognition in MRPRX2 appears instead to be in TM5, 
Asp1845.36 (see Supplementary Fig. 5c). Many other recognition residues do not overlap in 
sequence or structural placement. Indeed, the entire region surrounding Asp1845.36 and 
Glu1644.60 of the MRGPRX2 putative binding site is closed off from ligand contacts in the 
classical opioid binding site by Tyr3.33 – this is a smaller Thr110 in MRGPRX2. These 
seeming mismatches reflect that different receptor environments can recognize related ligand 
chemistry and the capacity for ligands to interact with receptors from different evolutionary 
families25,47 and different G protein coupling.
Certain caveats merit airing. We have not determined the structure of MRGPRX2 in 
complex with any of the ligands discussed here, and the modeling that we have used to 
interpret activity and to predict new molecules—however successfully—must remain 
tentative. Until the opioid actions at this receptor can be probed in vivo, so, too, must the 
physiological implications. We note that a prior study also suggested that MRGPRX2 is a 
novel “morphine receptor,” that mediates some of morphine’s analgesic activity48. Whereas 
this report certainly shares some similarity with our observations, we find, in contrast, that 
MRGPRX2 is more potently activated by (+)-, rather than (−)-, morphine, suggesting 
MRGRPX2 is unlikely to confer analgesia, as (+)-morphine is devoid of such activity35,49.
MRGPRX2 is a novel Gαq-coupled opioid-like receptor activated by endogenous 
prodynorphin-derived peptides and opioid compounds, including FDA-approved drugs and 
their metabolites. The discovery of selective and relatively potent MRGPRX2 agonist (R)-
ZINC-3573 and its inactive (S)-isomer provides researchers with a chemical probe pair to 
specifically modulate this receptor, illuminating its role in pathological reactions such as itch 
and potentially revealing a path for therapeutic design.
ONLINE METHODS
Cell Lines
HTLA cells were a gift from Dr. Richard Axel (Columbia University) and are maintained at 
low passage batches. FLP-IN/T-REX HEK-293-T cells were purchased from Invitrogen for 
ease of inducible stable cell line generation and were certified as HEK-T and mycoplasma-
free by Invitrogen. FLP-IN/T-REX cells were made into inducible stable cell lines according 
to the manufacturer’s instruction. The LAD2 human mast cell line was obtained from cells’ 
original source lab of Dr. Arnold Kirshenbaum and Dr. Dean Metcalfe 50 at the Laboratory 
of Infectious Diseases at the National Institutes of Health in Bethesda, MD and were 
maintained as per the their instructions. No further characterization of HTLA or LAD2 cells 
was performed, as the cells came from the source labs.
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Chemical Compounds
The nine libraries used in screening were the NCC-1 (NIH Clinical Collection), NCC-2 
(NIH Clinical Collection), NIMH Library, Tocris, Prestwick, LOPAC, Selleck, Spectrum, 
and the Roth Lab Collection (in-house). Opioid ligands were obtained from either Sigma 
Aldrich or synthesized.
Constructs
MRGPRX-Tango plasmids for MRGPRX1, MRGPRX2, or MRGPRX4 were made as was 
previously described6 MRGPRX2 constructs were also “de-Tangoized” to form the WT-
MRGPRX2 construct by inserting a STOP codon before the 3’ TEV site for transient 
transfection. MRGPRB2 insert was obtained from Dharmacon cDNA and subcloned into the 
PRESTO-Tango backbone.
PRESTO-Tango Assay Screening
HTLA cells (HEK-T cells stably expressing a β-arrestin2-TEV fusion protein and a tTa-
dependent luciferase reporter) were maintained in DMEM (Corning) containing 10% FBS, 2 
μg/mL puromycin and 100 μg/mL hygromycin B in a humidified atmosphere at 37°C with 
5% CO2. In brief, cells were plated to 50% confluency and transfected with a codon-
optimized MRGPRX-Tango construct using the calcium phosphate method 51. The next day, 
transfected cells were transferred to glass-bottomed, poly-L-lysine-coated white 384-well 
plates at a density of 20,000 cells/well. The following day, cells were treated with 10 μM 
concentrations of small molecules (in quadruplicate) diluted in drug buffer (1X HBSS with 
20 mM HEPES and 0.3% Bovine Serum Albumin, pH 7.4) and incubated for 18–24 hours. 
After drug incubation, medium was removed and 20 μL of Bright Glo (Promega) (diluted 
20-fold) was added to each well and incubated 15 minutes at room temperature. 
Luminescence was measured on a TriLux luminescence counter and analyzed as relative 
luminescent units (RLU) using GraphPad Prism. Compounds that increased the 
luminescence signal by two fold or greater were considered “actives” and were analyzed 
further using concentration-response curves. More detailed discussion of the PRESTO-
Tango assay can be found in6. Total number of dose response replicates for each compound 
can be found in Supplemental Table 2.
Intracellular Calcium Mobilization Assay
We generated a MRGPRX2-expressing tetracycline-inducible stable cell line containing the 
MRGPRX2 codon-optimized receptor sequence with a N-terminal FLAG tag using the FLP-
IN/T-REX Core Kit (Invitrogen) following the manufacturer’s instructions. MRGPRX2 
stable cells were maintained in DMEM containing 10% FBS, 100 μg/mL hygromycin B, and 
15 μg/mL blasticidin. For the calcium mobilization assay, cells were plated into glass 
bottomed, poly-L-lysine coated, black 384 well plates at a density of 20,000 cells/well in 
medium containing 1% dialyzed FBS, 1 μg/mL tetracycline, 100 IU/mL penicillin and 100 
μg/ml streptomycin and incubated 24 hours. Following tetracycline induction, medium was 
removed and cells were loaded with 20 μl/well of 1X FLIPR Calcium dye (Molecular 
Devices) and 2.5 mM probenic acid, for 1 hour in a humidified environment at 37°C with 
5% CO2. For mast cell calcium experiments, cells were seeded at a density of 50,000 cells/
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well in Tyrode’s buffer containing 1X calcium dye and incubated for 1 hour before treatment 
and analysis. After dye loading, baseline was measured for 10 seconds before drug 
treatment, and then cells were treated with 10 μL of 3x concentrated drug in drug buffer (1X 
HBSS with 20 mM HEPES and 2.5 mM probenic acid, pH 7.4) in 16 point concentration 
response curves from 10 μM to 0.003 nM. Fluorescence was measured for an additional 120 
seconds and data was analyzed using GraphPad Prism. Total number of dose response 
replicates for each compound can be found in Supplemental Table 2.
β-hexosaminidase Assay
LAD2 cells were maintained in Stem-Pro34 medium (GIBCO) supplemented with 
StemPro34 Supplement (GIBCO), 2 mM L-Glutamine, 100 U/mL penicillin/streptomycin, 
and recombinant human stem cell factor (100 ng/ml) (Peprotech) as described in52. For the 
assay, adapted from 53, cells were incubated in fresh medium for 18 hours prior to the 
experiment. If testing IgE activation, cells were also incubated with biotin-labeled IgE 
during this time. Then, cells were washed twice in Tyrode’s buffer (20 mM HEPES with 134 
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.5 mM glucose, and 0.3% bovine 
serum albumin, pH 7.4) and seeded at 10,000 cells per well of V-bottom clear 96 well plates 
in 90 μL of Tyrode’s buffer. Drugs were diluted at single concentrations or in 8-point 
concentration-response curves at a 10X working concentration in Tyrode’s buffer and 10 μL 
drug, or streptavidin for biotin-labeled IgE samples, and were added in triplicate to the 90 
μL mast cell suspension. Drugs and cells were incubated for 30 minutes in a humidified 
incubator without CO2 at 37°C. After drug incubation, plates were centrifuged at 250g for 5 
minutes and 30 μl supernatant was added to new 96 well plates containing 10 μL of 10 μM 
4-nitrophenyl N-acetyl-β-D-glucosaminide (NAG) diluted in 0.1M Citrate Buffer (49.5% 
0.1M citric acid and 50.5% 0.1M sodium citrate, pH 4.5). The remaining supernatant was 
discarded and cells were lysed by adding 100 μl of Tyrode’s buffer with 0.1% Triton-X-100 
to the pellets and mixed. Thirty μL of lysate was added to 10 μL of 10 μM NAG. All plates 
were incubated for 90 minutes in a humidified incubator without CO2 at 37°C. Lastly, 100 
μL of bicarbonate buffer (88 mM Na2CO3, 40 mM NaHCO3, pH 10) was added to stop the 
reaction, inducing a color change that was measured on an absorbance plate reader (BMG 
Labtech POLARstar Omega) at 405 nm. Results were analyzed by dividing the released 
fraction by the total fraction (released + lysed) and multiplying by 100 to get a percentage 
degranulation. To correct for spontaneous degranulation, average percent degranulation for 
vehicle-treated wells was subtracted from drug-treated wells. Total number of dose response 
replicates for each compound is reflected in figures and figure legends.
siRNA Knockdown and qPCR Analysis
Using TransIT 20/20 transfection reagent (Mirus), 25 nM of each siRNA (Dharmacon # 
EQ-005666-00-0002, set of 4 distinct MRGPRX2 siRNAs) or the non-targeting siRNA 
control (Dharmacon # D-001910-10-05) was prepared in 250 μL of OPTI-MEM with 5 μL 
TransIT per reaction. After 30 minutes, the transfection mixture was added dropwise to 1.2 
million mast cells/well of a 6-well plate and allowed to incubate 72 hours. After 72 hours, 
200,000 cells were removed for use in the β-hexosaminidase assay and 1 million cells were 
assayed using qRT-PCR analysis with the High-Capacity cDNA Reverse Transcription Kit 
(Life Technologies) following the manufacturer’s instructions and TaqMan Universal Master 
Lansu et al. Page 13
Nat Chem Biol. Author manuscript; available in PMC 2017 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mix II with UNG (Life Technologies) and TaqMan Gene Expression Assay for MRGPRX2 
(Life Technologies #4331182, Hs00365019_s1) following the manufacturer’s suggested 
protocol.
Significance calculations of siRNA experiments
To assess significance, we used GraphPad Prism to perform a Two-way ANOVA and Sidak 
post-hoc with an alpha value of 0.05. Total number of replicates is reflected in figure legends 
and figures.
Homology Modeling
The alignment for the construction of the MRGPRX2 models was generated using 
PROMALS3D54, and homology models were built with MODELLER-9v827 using the 
crystal structure of the κ-opioid receptor (PDB code 4DJH) as the template. The homology 
models were aligned against the entire MRGPRX and opioid receptor family. The alignment 
was manually edited to remove the amino and carboxy termini that extended past the 
template structure, to remove the engineered T4 lysozyme, and to create different alignments 
of the flexible and non-conserved second extracellular loop (EL2); the final resulting 
sequence alignment between the template opioid structure and the MRGPRX receptors is 
shown in Supp. Fig 5c. Three models were built from each of 180 elastic network models 
(ENMs), produced by the program 3K-ENM28, for a total of 540 models built during each 
iterative round of model refinement. Although EL2 is significantly shorter in MRGPRX2 
than in other GPCRs, and it lacks the conserved disulfide bond between TM3 and EL2, an 
additional 540 models were also built forcing a putative disulfide between Cys168 in EL2 
and Cys180 in TM5.
Model evaluation
Models were ranked on the basis of prioritizing active opioids (dextromethorphan) over the 
rest of the inactive PRESTO-Tango library that was used in the β-arrestin screen, as well as 
over property-matched decoy small molecules. We further insisted that in its docked pose, 
dextromethorphan engaged in an ion pair between its charged nitrogen and an anionic side 
chain in MRGPRX2. The entire PRESTO-Tango library was docked to analogous 4DJH 
ligand binding site in the modeled MRGPRX2 receptors for several rounds of iterative 
binding site refinement. In each round, the top-ranked models were examined for a binding 
pose that made hydrophobic and electrostatic interactions with the receptor, including the 
key positive-negative charge coordination. Residues within 6 Å of the dextromethorphan 
pose were then minimized around the docked ligand with PLOP 55. The PRESTO-Tango 
library was then re-docked into this optimized binding site for each model. This refinement 
continued for several cycles until the top-ranked models all converged to the same 
dextromethorphan pose, with the top-scoring model chosen as the final one. Structural 
models (PDB files) of characteristic MRGPRX2-modelled complexes (with 
dextromethorphan and ZINC-9232) are shown in the Supplementary Data.
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Virtual screens
We used DOCK 3.6 to screen the ZINC database (http://zinc15.docking.org/) (Results). The 
flexible ligand sampling algorithm in DOCK 3.6 superimposes atoms of the docked 
molecule onto binding site matching spheres, which represent favorable positions for 
individual ligand atoms. Forty-five matching spheres were used, with each respectively 
starting from the previous refinement round’s best pose of dextromethorphan. The degree of 
ligand sampling is determined by the bin size, bin size overlap, and distance tolerance, set at 
0.4 Å, 0.1 Å and 1.5 Å, respectively, for both the matching spheres and the docked 
molecules. The complementarity of each ligand pose was scored as the sum of the receptor–
ligand electrostatic and van der Waals’ interaction energies and corrected for context-
dependent ligand desolvation using QNIFFT point-charge Poisson-Boltzmann electrostatics 
models56. Partial charges from the united-atom AMBER57 force field were used for all 
receptor atoms; ligand charges and initial solvation energies were calculated using 
AMSOL 58,59 (http://comp.chem.umn.edu/amsol/). The best scoring conformation of each 
docked molecule was then subjected to 100 steps of rigid-body minimization.
Selection of potential ligands for testing
We docked the approximately 3.7 million commercially available molecules of the lead-like 
subset of the ZINC database to the final MRGPRX2 models. The full hit list was 
automatically filtered to remove molecules that possess high internal energy, non-physical 
conformations, which are not well modeled by our scoring function. The reported rankings 
reflect this filtering. From the top 0.13% (~5,000 molecules) of the docked ranking list, 20 
compounds were chosen for testing, based on complementarity to the binding site and 
presence of predicted charge interactions with Glu1644.60 and Asp1845.36, mimicking those 
predicted for dextromethorphan.
Chemistry General Procedures
HPLC spectra for all compounds were acquired using an Agilent 1200 Series system with 
DAD detector. Chromatography was performed on a 2.1×150 mm Zorbax 300SB-C18 5 μm 
column with water containing 0.1% formic acid as solvent A and acetonitrile containing 
0.1% formic acid as solvent B at a flow rate of 0.4 mL/min. The gradient program was as 
follows: 1% B (0 1 min), 1 99% B (1 4 min), and 99% B (4 8 min). High-resolution mass 
spectra (HRMS) data were acquired in positive ion mode using an Agilent G1969A API-
TOF with an electrospray ionization (ESI) source. Nuclear Magnetic Resonance (NMR) 
spectra were acquired on eith a Bruker DRX-600 spectrometer (600 MHz 1H, 150 
MHz 13C). Chemical shifts are reported in ppm (δ). HPLC was used to establish the purity 
of target compounds. All final compounds had > 95% purity using the HPLC methods 
described above.
7-Chloro-5-phenylpyrazolo[1,5-a]pyrimidine—The title compound was synthesized 
according to a known literature procedure.60 To a solution of 3-aminopyrazole (2.0 g, 24 
mmol) in acetic acid (15 mL) was added ethylbenzoylacetate (4.7 mL, 27 mmol). The 
resulting reaction mixture was refluxed for 3 h before being cooled to rt and concentrated. 
The solid residue was diluted with EtOAc and filtered to afford 5-phenylpyrazolo[1,5-
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a]pyrimidin-7(4H)-one (4.19 g, 83%) as white solid. This intermediate (1.0 g, 4.7 mmol) 
was dissolved in POCl3 (5.0 mL, 55 mmol). To the resulting solution was added pyridine 
(0.25 mL, 3.1 mmol) at rt. After being stirred for 3 days at rt, the reaction mixture was 
diluted with Et2O (50 mL) and filtered. The solid was rinsed with Et2O (2 x). The combined 
Et2O solution was cooled to 0 °C and treated with ice and water. The organic layer was 
washed with water (2 x) and brine (2 x). The organic layer was dried (Na2SO4) and 
concentrated to give the tittle compound (0.82 g, 76%) as pale yellow solid. 1H NMR (600 
MHz, CDCl3) δ 8.23 (d, J = 2.3 Hz, 1H), 8.12 – 8.04 (m, 2H), 7.58 – 7.48 (m, 3H), 7.45 (s, 
1H), 6.84 (d, J = 2.3 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 156.2, 149.8, 146.1, 139.2, 
136.5, 131.0, 129.2 (2C), 127.5 (2C), 105.8, 98.8. HRMS (ESI-TOF) m/z: [M+H]+ calcd for 
C12H9ClN3, 230.0485; found: 230.0484.
(R)-N,N-Dimethyl-1-(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-3-amine 
((R)-ZINC-3573)—To a solution of 7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (0.069 g, 
0.3 mmol) in dioxane (2 mL) was added DIEA (0.19 mL, 0.6 mmol), followed by (R)-(+)-3-
(dimethylamino)pyrrolidine (0.038 g, 0.33 mmol). The resulting solution was stirred for 16 h 
at rt before being concentrated and purified by silica gel column to provide the title 
compound (0.070 g, 76%). 1H NMR (600 MHz, CDCl3) δ 8.02 – 7.97 (m, 2H), 7.95 (d, J = 
2.3 Hz, 1H), 7.51 – 7.40 (m, 3H), 6.48 (d, J = 2.3 Hz, 1H), 6.12 (s, 1H), 4.30 (t, J = 8.8 Hz, 
1H), 4.23 (t, J = 9.8 Hz, 1H), 4.02 (q, J = 9.4 Hz, 1H), 3.83 (t, J = 9.5 Hz, 1H), 2.90 – 2.82 
(m, 1H), 2.36 (s, 6H), 2.29 – 2.21 (m, 1H), 2.01 – 1.91 (m, 1H). 13C NMR (151 MHz, 
CDCl3) δ 157.5, 151.8, 147.9, 143.8, 139.2, 129.6, 128.7 (2C), 127.3 (2C), 94.9, 86.2, 65.2, 
55.0, 50.1, 44.5 (2C), 30.1. HRMS (ESI-TOF) m/z: [M+H]+ calcd for C18H22N5, 308.1875; 
found: 308.1871.
(S)-N,N-Dimethyl-1-(5-phenylpyrazolo[1,5-a]pyrimidin-7-yl)pyrrolidin-3-amine 
((S)-ZINC-3573)—The title compound (0.075 g, 81%) was prepared using the same 
synthetic procedure for the preparation of (R)-ZINC-3573 with (S)-(+)-3-
(dimethylamino)pyrrolidine (0.038 g, 0.33 mmol). 1H NMR (600 MHz, CDCl3) δ 8.05 – 
7.97 (m, 2H), 7.95 (d, J = 2.3 Hz, 1H), 7.52 – 7.39 (m, 3H), 6.48 (d, J = 2.3 Hz, 1H), 6.12 (s, 
1H), 4.30 (t, J = 8.8 Hz, 1H), 4.23 (t, J = 9.8 Hz, 1H), 4.02 (q, J = 9.3 Hz, 1H), 3.83 (t, J = 
9.5 Hz, 1H), 2.91 – 2.81 (m, 1H), 2.36 (s, 6H), 2.30 – 2.21 (m, 1H), 2.02 – 1.91 (m, 
1H). 13C NMR (151 MHz, CDCl3) δ 157.5, 151.8, 147.9, 143.8, 139.2, 129.6, 128.7 (2C), 
127.3 (2C), 94.9, 86.2, 65.2, 55.0, 50.1, 44.5 (2C), 30.1. HRMS (ESI-TOF) m/z: [M+H]+ 
calcd for C18H22N5, 308.1875; found: 308.1872.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Validation of MRGPRX2 and MRGPRB2 Agonists
A–D) Average concentration response curves in the FLIPR intracellular calcium release 
assay (n=3 in triplicate) in MRGPRX2-inducible cells, designated +X2 or –X2 for +/
−tetracycline-induced receptor expression, for previously published MRGPRX2 agonists. Y 
axis is fold change calcium release over basal. E) Concentration response curves in FLIPR 
intraceullar calcium release assay for stable cell lines expressing either the proposed 
orthologues human MRGPRX2 (solid lines) or mouse MRGPRB2 (dotted lines) with X2-
activating peptides Cortistatin-14 and Substance P and small molecule agonist TAN-67. Y 
axis is fold change calcium release over basal (n=3 in quadruplicate) F) Concentration 
response curves for Cortistatin-14, Substance P, and small molecule agonist TAN-67 with 
MRGPRX2-Tango (solid lines) and MRGPRB2-Tango (dotted lines) in the PRESTO-Tango 
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arrestin recruitment assay (n=3 in triplicate). Y axis is fold change response over basal 
luminescent signal. All error bars represent SEM.
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Figure 2. PRESTO-Tango Screening of MRGPRX2 reveals new agonists
A) Venn diagram depicting pooled PRESTO-Tango screening actives for MRGPRX1, 
MRGPRX2, and MRGPRX4 for all hits with greater than 2-fold activation over basal 
(known false-positives and duplicates excluded). B-C) Average concentration response 
curves (n=3 in triplicate wells for all, except ADL5859 n=1) for the five compounds from 
the screening show low micromolar activation of MRGPRX2. D) Concentration response 
curve for previously published MRGPRX2 peptide agonists at the MRGPRX2-Tango 
construct. Y axes shown as % of TAN-67 activity. All error bars represent SEM.
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Figure 3. MRGPRX2 is activated by many opioid scaffolds
A–D) Average concentration response curves (n=3 in triplicate) for structurally related 
compounds (morphinans, benzomorphans, morphine and analogues, and codeine and 
analogues, respectively) in intracellular calcium release assay where Y axis is fold change 
calcium release over baseline. Error bars represent SEM. E) Summary of major findings in 
structure activity relationships for opioid scaffolds at MRGPRX2, including size of N-
substituent, stereochemistry of chiral centers, and bulk on the 3-position of the morphinan.
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Figure 4. MRGPRX2 is preferentially activated by prodynorphin-derived peptides
A–B) Averaged concentration response curves (n=2 or 3 in triplicate, see Supplementary 
Table 2) for pro-dynorphin-derived peptides in MRGPRX2 Tet-On cells where Y axis is fold 
change calcium release over baseline. Error bars represent SEM. C, D) Average 
concentration response curves (n=2 or 3 in triplicate, see Supplementary Table 2) depicting 
non-prodynorphin-derived peptides with minimal activity compared to dynorphins in A and 
B. Error bars represent SEM.
Lansu et al. Page 24
Nat Chem Biol. Author manuscript; available in PMC 2017 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. In silico MRGPRX2 homology modeling predicts a selective agonist
Workflow depicting MRGPRX2 homology model construction (top left) followed by 
identification of a putative binding site (top middle) that was confirmed by testing the 
mutations E164Q and D184N (top right, average dose response, n=3 in triplicate, shown 
with dextromethorphan (DXM). Then, ~3.7 million molecules were docked to predict the 
agonist ZINC-9232 (bottom left). Further iteration and testing revealed the tool and selective 
compounds (S)- and (R)-ZINC-5373 (bottom middle and right). Docking pose of selective 
compound is supported with mutation experiments in PRESTO-Tango (bottom right, 
average dose response curve, average of n=4 in triplicate). Error bars on graphs shown is 
representative of SEM.
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Figure 6. MRGPRX2 mediates intracellular calcium release and degranulation in the LAD2 
human mast cell line
A) Average concentration response for MRGPRX2-selective agonists ZINC-6932 and 
ZINC-3573 in the calcium mobilization assay (n=3 in triplicate). B) Average concentration 
response (n=3 in triplicate) for MRGPRX2 probes ZINC-3573 (R) and ZINC-3573 (S) in the 
β-hexosaminidase degranulation assay. C). Bar graph depicting fold change %degranulation 
(baseline = average DMSO of all plates) induced by EC80 concentration of drug following 
25 nM MRGPRX2 siRNA transfection; NT = Non Targeting pool, siRNA 2+3 = MRGPRX2 
siRNA pool. Statistics = Two-way ANOVA with a Sidak post-hoc test (p <0.05 = *, 
p=0.031, 0.031, 0.033, and 0.017 for TAN, Dyn, Morphine, and ZINC-3573, respectively). 
Lansu et al. Page 26
Nat Chem Biol. Author manuscript; available in PMC 2017 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
n=3 for all except ZINC-3573, n=2. All replicates in triplicate wells. D) Concentration 
response curves for MRGPRX2-activating opioid ligands and the structurally related, κ-
opioid receptor ligand (−)-cyclazocine in the calcium mobilization assay (n=3 in triplicate). 
E) Average concentration response in intracellular calcium release with MRGPRX2-
activating (+/−)-TAN-67 and canonical opioid receptor ligands DADLE, DAMGO, 
Salvinorin A, and BW373U86 (n=3 in triplicate). F) Bar graph depicting baseline 
normalized percent degranulation induced for each 10 μM (+/−)-TAN-67, DMSO, and 
calcium ionophore ionomycin in the presence of absence of biotin-labeled IgE antibodies. 
(Streptavidin in all wells, average of n=2 in triplicate.) G). Average concentration response 
curves for MRGPRX2-activating opiates (n=3 in triplicate.) in the β-hexosaminidase 
degranulation assay. H) Degranulation concentration response with canonical opioid 
receptor agonists and MRGPRX2-activating (+/−)-TAN-67, (n=3 in triplicate). All error bars 
demonstrate SEM.
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